The FDA Just Approved a First-of-its-Kind Drug that Targets Cancer’s Genes
This week the FDA granted approval to the cancer drug Keytruda, an immunotherapy drug. This is a milestone — the first time a cancer drug has received approval for targeting a particular biomarker rather than a location in the body.
In other words, this development marks a new way of approaching cancer treatments. Now, drug developers are validated in developing new medications focused on the genetics of both patient and tumor, rather than the harsher, scorched-earth tactics of the past that kill healthy and sick cells alike, such as chemotherapies.
From our very good friends over at futurism.com